Hutchison China Meditech Ltd (LON:HCM) Rating Reaffirmed
Beaufort Securities has decided to restate their Buy rating on Hutchison China Meditech Ltd (LON:HCM) in analysts report finalized on Wednesday, 9 December.
From a total of 1 analysts covering Hutchison China Meditech Ltd (LON:HCM) stock, 0 rate it a ”Buy”, 1 a “Sell”, and 0 a ”Hold”. This means that 0% of the ratings are positive. Hutchison China Meditech Ltd was the topic of 2 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. Beaufort Securities maintained shares on November 2 with “Buy” rating.
Approximately 2,059 shares of stock traded hands. Hutchison China MediTech Limited (LON:HCM) has risen 64.87% since May 12, 2015 and is uptrending. It has outperformed by 65.66% the S&P500.
Hutchison China MediTech Limited is a China-based, globally-focused healthcare group. The company has a market cap of 1.60 billion GBP. The Firm researches, develops, makes and sells pharmaceuticals and health-related consumer products. It has 2456.52 P/E ratio. The Company’s Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.